1 year return (CAGR)
-53.67%
Abionyx Pharma SA Exchange (PA, EUR)
ABNX.PA
1.43
-0.02 (-1.16%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
5.39%
5 year return (CAGR)
-0.03%
10 year return (CAGR)
-14.96%
Adobe 2026 Q3 – Is sentiment driving the price?
Read MoreMarketcap
66.92M
Price/Sales
8.11
Ent value
60.90M
Price/Book
4.27
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
11.28%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.64 |
| Daily high | 1.65 |
| Daily low | 1.51 |
| Daily Volume | 247K |
| All-time high | 14.14 |
| 1y analyst estimate | 9.83 |
| Beta | 0.46 |
| EPS (TTM) | -0.35 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ABNX.PA | S&P500 | |
| Current price drop from All-time high | -89.87% | -0.14% |
| Highest price drop | -98.55% | -56.47% |
| Date of highest drop | 25 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -78.95% | -10.66% |
| Avg time to new high | 295 days | 12 days |
| Max time to new high | 2863 days | 1805 days |
News
TOULOUSE, France & FULLERTON, Calif., October 07, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing innova...
October 7, 2026
TOULOUSE, France, October 02, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):
October 2, 2026
TOULOUSE, France & FULLERTON, Calif., October 02, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for PEA-PME) ("Abionyx" or the "Company"), a next-generation biopharmaceutical c...
October 2, 2026
WOIPPY, France, October 01, 2026--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, health...
October 1, 2026
TOULOUSE, France & FULLERTON, Calif., September 23, 2026--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for the PEA PME), a next-generation biopharmaceutical company developing inno...
September 23, 2026
TOULOUSE, France & FULLERTON, Calif., September 10, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative th...
September 10, 2026
TOULOUSE, France & FULLERTON, Calif., August 27, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharmaceutical company developing innovative thera...
August 27, 2026
TOULOUSE, France, July 06, 2026--Regulatory News: ABIONYX Pharma (Paris:ABNX):
July 6, 2026
TOULOUSE, France & FULLERTON, Calif., June 30, 2026--Regulatory News: ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing in...
June 30, 2026
WOIPPY, France, September 10, 2026--Regulatory News: ABL Diagnostics (Euronext Paris: ABLD - ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software and clin...
September 10, 2026